Dehydroepiandrosterone and the endocrine aging process

Current Opinion in Endocrinology and Diabetes

Volumn 3, Issue 2, 1996, Pages 117-124

  Svec, Frank ^a   Porter, Johnny R ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002455726     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-199604000-00008     Document Type: Article

References (63)

1. Regelson W, Loria R, Kalimi M: Dehydroepiandrosterone (DHEA): the "mother steroid." Ann N Y Acad Sci 1992, 719:553-563.
2. Regelson W, Kalimi M: Dehydroepiandrosterone (DHEA): the multifunctional steroid II. Ann N Y Acad Sci 1994, 719:564-575.
3. Wright BE, Porter JR, Browne ES, Svec F: Antiglucocorticoid action of dehydroeplandrosterone in young obese Zucker rats. Int J Obes 1992, 16:579-583.
4. Nestler JE, Clore JN, Blackard WG: Dehydroepiandrosterone: the "missing link" between hyperinsulinemia and atherosclerosis? FASEB J 1992, 6:3073-3075.
5. Bilger AB: Forever young. The Sciences 1995, 35:26-31. An entertaining and insightful news reporter's interview with many of the individuals who attended the New York Academy of Science's meeting on dehydroepiandrosterone and aging in Washington, DC in 1995. The article gives both a readable overview of the field as well as some caricatures of the individuals shaping research in the field.
6. Barrett-Connor E, Khaw KT, Yen SSC: A prospective study of dehydroeplandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med 1986, 315:1519-1524.
7. Eich DM, Nestler JE, Johnson DE, Dworkin GH, Ko D, Wechsler AS, Hess ML: Inhibition of accelerated coronary atherosclerosis with deny droepiandrosterone in the heterotopic rabbit model of cardiac transplantation. Circulation 1993, 87:261-269.
8. Haffa AL, MacEwen EG, Kurzman ID, Kemnitz JW: Hypocholesterolemic effect of exogenous dehydroepiandrosterone administration in the rhesus monkey. In Vivo 1994, 8:993-997. A recent clear demonstration that dehydroepiandrosterone can alter cholesterol levels in primates. Duration of treatment and dosage needed to change monkey cholesterol may prove important in designing human studies.
9. Herrington DM, Gordon GB, Achuff SC, Trejo JF, Weisman HF, Kwiterovich PO Jr, Pearson TA: Plasma dehydroepiandrosterone and dehydroepiandrosterone sulfate in patients undergoing diagnostic coronary angiography. J Am Coll Cardiol 1990, 16:862-870.
10. Mitchell LE, Sprecher DL, Borecki IB, Rice T, Laskarzewski PM, Rao DC: Evidence for an association between dehydroepiandrosterone sulfate and nonfatal, premature myocardial infarction in males. Circulation 1994, 89:89-93.
11. LaCroix AZ, Yano K, Reed DM: Dehydroepiandrosterone sulfate, incidence of myocardial infarction, and extent of atherosclerosis in men. Circulation 1992, 86:1529-1535.
12. Newcomer LM, Manson JE, Barbieri RL, Hennekens CH, Stampfer MJ: Dehydroepiandrosterone sulfate and the risk of myocardial infarction in US male physicians: a prospective study. Am J Epidemiol 1994, 140:870-875.
13. Contoreggi CS, Blackman MR, Andres R, Muller DC, Lakatta EG, Fleg JL, Harman SM: Plasma levels of estradiol, testosterone, and DHEAS do not predict risk of coronary artery disease in men. J Androl 1990, 11:460-70.
14. Hauner H, Stangl K, Burger K, Busch U, Blomer H, Pfeiffer EF: Sex hormone concentrations in men with angiographically assessed coronary artery disease: relationship to obesity and body fat distribution. Klin Wochenschr 1991, 69:664-668.
15. Slowmska-Srzednicka J, Malczewska B, Srzednicki M, Chotkowska E, Brezezinska A, Zgliczynski W, Ossowski M, Jeske W, Zgliczynski S, Sadowski Z: Hyperinsulinaemia and decreased plasma levels of dehydroepiandrosterone sulfate in premenopausal women with coronary heart disease. J Intern Med 1995, 237:465-472.
16. Barrett-Connor E, Goodman-Gruen D: Dehydroepiandrosterone sulfate does not predict cardiovascular death in postmenopausal women: the Rancho Bemardo study. Circulation 1995, 91:1757-1760.
17. Coleman MP, Key TJ, Wang DY, Hermon C, Fentiman IS, Allen DS, Jarvis M, Pike MC, Sanders TA: A prospective study of obesity, lipids, apolipoproteins and ischaemic heart disease in women. Atherosclerosis 1992, 92:177-185.
18. Hautanen A, Manttari M, Manninen V, Tenkanen L, Huttunen JK, Frick MH, Adlercreutz H: Adrenal androgens and testosterone as coronary risk factors in the Helsinki Heart Study. Atherosclerosis 1994, 105:191-200.
19. Svec F, Hilton CW, Wright B, Browne E, Porter JR: The effect of DHEA given chronically to Zucker rats. Proc Soc Exp Biol Med 1994, 209:92-97.
20. Cleary MP: The antiobesity effect of dehydroepiandrosterone in rats. Proc Soc Exp Biol Med 1991, 96:8-16.
21. Welle S, Jozefowicz R, Statt M: Failure of dehydroepiandrosterone to influence energy and protein metabolism in humans. J Clin Endocrinol Metab 1990, 71:1259-1264.
22. Usiskin KS, Butterworth S, Clore JN, Arad Y, Ginsberg HN, Blackard WG, Nestler JE: Lack of effect of dehydroeplandrosterone in obese men. Int J Obes 1990, 14:457-463.
23. Zumoff B, Strain GW, Heymsfield SB, Lichtman S: A randomized double-blind crossover study of the antiobesity effects of etiocholanedione. Obes Res 1994, 2:13-18. The most recent positive report on the effect of a dehydroepiandrosterone analogue on human obesity. If the finding is reproducible it may trigger a search for other synthetic compounds that act like dehydroepiandrosterone on obesity but resist being converted into sex steroids.
24. Williams DB, Boyden TW, Pamenter RW, Lohman TG, Going SB: Relationship of body fat percentage and fat distribution with dehydroepiandrosterone sulfate in premenopausal females. J Clin Endocrinol Metab 1993, 77:80-85.
25. Haffner SM, Valdez RA, Stern MP, Katz MS: Obesity, body fat distribution and sex hormones In men. Int J Obes Relat Metab Disord 1993, 17:643-649.
26. Araneo BA, Shelby J, Li GZ, Hu W, Daynes RA: Administration of dehydroepiandrosterone to burned mice preserves normal immunologic competence. Arch Surg 1993, 128:318-325.
27. Araneo B, Daynes R: Dehydroepiandrosterone functions as more than an antiglucocorticoid in preserving immunocompetence after thermal injury. Endocrinology 1995, 136:393-401. A pertinent report that shows the action of dehydroepiandrosterone on the immune system and investigates carefully whether it exerts this action through a glucocorticoid pathway. It again raises the question: if dehydroepiandrosterone is not an antiglucocorticoid, into what category of steroids should it be placed?
28. Weksler ME: Immune senescence and adrenal steroids: immune dysregulation and the action of dehydroepiandrosterone (DHEA) in old animals. Eur J Clin Pharmacol 1993, 45(suppl 1):S21-S23; S44-S44.
29. Garg M, Bondada S: Reversal of age-associated decline in immune response to pnu-imune vaccine by supplementation with the steroid hormone dehydroepiandrosterone. Infect Immun 1993, 61:2238-2241.
30. Araneo BA, Woods ML II, Daynes RA: Reversal of the immunosenescent phenotype by dehydroepiandrosterone: hormone treatment provides an adjuvant effect on the immunization of aged mice with recombinant hepatitis B surface antigen. J Infect Dis 1993, 167:830-840.
31. Van Vollenhoven RF, Engleman EG, McGuire JL: An open study of dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum 1994, 37:1305-1310.
32. Baulieu EE: Neurosteroids: a new function in the brain. Biol Cell 1991, 71:3-10.
33. Robel P, Bourreau E, Corpechot C, Dang DC, Halberg F, Clarke C, Haug M, Schlegel ML, Synguelakis M, Vourch C, Baulieu E-E: Neuro-steroids: 3β-hydroxy-5-derivatives in rat and monkey brain. J Steroid Biochem 1987, 27:649-655.
34. Flood JF, Morley JE, Roberts E: Memory-enhancing effects in male mice of pregnenolone and steroids metabolically derived from it Proc Natl Acad Sci U S A 1992, 89:1567-1571.
35. Robel P, Bourreau E, Corpechot C, Dang DC, Halberg F, Clarke C, Haug M, Schlegel ML, Synguelakis M, Vourch C, Baulieu EE: Neuro-steroids 3β-hydroxy-Δ5-derivatives in rat and monkey brain. J Steroid Biochem 1987, 27:649-655.
36. Abadie JM, Wright B, Correa G, Browne ES, Porter JR, Svec F: Effect of dehydroepiandrosterone on neurotransmitter levels and appetite regulation of the obese Zucker rat Diabetes 1993, 42:662-669.
37. Porter JR, Abadie JM, Wright BE, Browne ES, Svec F: The effect of discontinuing dehydroepiandrosterone supplementation on Zucker rat food Intake and hypothalamic neurotransmitters. Int J Obes 1995, 19:480-488.
38. Majewska MD, Demirgoren S, Spivak CE, London ED: The neurosteroid dehydroepiandrosterone sulfate is an allosteric antagonist of the GABA A receptor. Brain Res 1990, 526:143-146.
39. Spivak CE: Desensitization and noncompetitive blockage of GABA A receptors in ventral midbrain neurons by a neurosteroid dehydroepiandrosterone sulfate. Synapse 1994, 16:113-122.
40. Sunderland T, Merril CR, Harrington MG, Lawlor BA, Molchan SE, Martinez R, Murphy DL: Reduced plasma dehydroepiandrosterone concentrations in Alzheimer's disease. Lancet 1989, 8662:570.
41. Leblhuber F, Neuibauer C, Peichl M, Reisecker F, Steinparz FX, Windhager E, Dienstl E: Age and sex differences of dehydroepiandrosterone sulfate (DHEAS) and cortisol (CRT) plasma levels in normal controls and Alzheimer's disease (AD). Psychopharmacology (Berl) 1993, 111:23-26.
42. Casson PR, Faquin LC, Stentz FB, Straughn AB, Andersen RN, Abraham GE, Buster JE: Replacement of dehydroeplandrosterone enhances T- lymphocyte insulin binding in postmenopausal women. Fertil Steril 1995, 63:1027-1031.
43. Morales AJ, Nolan JJ, Nelson JC, Yen SSC: Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 1994, 78:1360-1367. This paper shows that it takes only a low dose of supplemental dehydroepiandrosterone to return serum levels in older individuals to those of younger controls, but this supplementation has surprisingly few dramatic effects on metabolic parameters of aging. However, it has a dramatic effect on the hard- to-define sense of well-being. A clue that the central nervous system may be the most pertinent site to search for the site of action for dehydroepiandrosterone.
44. Thomas G, Frenoy N, Sylvie L, Sabag-Lanoe R, Baulieu EE, Debuire B: Serum dehydroepiandrosterone sulfate levels as an Individual marker. J Clin Endocrinol Metab 1994, 79:1273-1276.
45. Orentreich N, Brind JL, Bogelman JH, Andres R, Baldwin H: Long-term longitudinal measurements of plasma dehydroepiandrosterone sulfate in normal men. J Clin Endocrinol Metab 1992, 75:1002-1004.
46. Bélanger A, Candas B, Dupont A, Cusan L, Diamond P, Gomez JL, Labne F: Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J Clin Endocrinol Metab 1994, 79:1086-1090.
47. Hochberg RB, Pahuja SL, Zielinski JE, Lamer JM: Steroidal fatty acid esters. J Steroid Biochem Mol Biol 1991, 40:577-584.
48. Beer NA, Jakubowicz DJ, Beer RM, Nestler JA: The calcium channel blocker amlodipine raises serum dehydroepiandrosterone sulfate and androstenedione, but lowers serum cortisol, in insulin-resistant obese and hypertensive men. J Clin Endocrinol Metab 1993, 76:1464-1469.
49. Beer NA, Jakubowicz DJ, Beer RM, Arocria IR, Nestler JA: Effects of nitrendipine on glucose tolerance and serum insulin and dehydroepiandrosterone sulfate levels in insulin-resistant obese and hypertensive men. J Clin Endocrinol Metab 1993, 76:178-182.
50. Nestler JE, Beer NA, Jakubowicz DJ, Colomba C, Beer RM: Effects of insulin reduction with benfluorex on serum dehydroepiandrosterone (DHEA), DHEA sulfate, and blood pressure in hypertensive middle- aged and elderly men. J Clin Endocrinol Metab 1995, 80:700-706.
51. Salvini S, Stampfer MJ, Barbieri RL, Hennekens CH: Effects of age, smoking and vitamins on plasma DHEAS levels: a cross-sectional study in men. J Clin Endocrinol Metab 1992, 74:139-143.
52. Blauer KL, Poth M, Rogers WM, Bernton EW: Dehydroepiandrosterone antagonizes the suppressive effects of dexamethasone on lymphocyte proliferation. Endocrinology 1991, 129:3174-3179.
53. Browne ES, Wright BE, Porter JR, Svec F: Dehydroepiandrosterone: antiglucocorticoid action in mice. Am J Med Sci 1992, 303:366-371.
54. Kalimi M, Shafagoj Y, Loria R, Padgett D, Regelson W: Anti-glucocorticoid effects of dehydroeplandrosterone (DHEA). Mol Cell Biochem 1994, 131:99-104. Only when the molecular mechanism of action of dehydroepiandrosterone is known will it be possible to understand how it interacts with glucocorticoid hormones. Although dehydroepiandrosterone may not work through currently envisioned mechanisms that involve the glucocorticoid receptor, this paper reviews much of the evidence that at least some of its actions involve antagonizing the effects of glucocorticoids.
55. Kalimi M, Regelson W: Physicochemical characterization of [3H]DHEA binding in rat liver. Biochem Biophys Res Commun 1988, 156:22-29.
56. Meikle AW, Dorchuck RW, Araneo BA, Stringham JD, Evans TG, Spruance SL, Daynes RA: The presence of a dehydroepiandrosterone- specific receptor binding complex in murine T cells. J Steroid Biochem Mol Biol 1992, 42:293-304.
57. Yamada J, Sugiyama H, Sakuma M, Suga T: Specific binding of dehydroepiandrosterone sulfate to rat liver cytosol: a possible association with peroxisomal enzyme Induction. Biochem Biophys Acta 1994, 1224:139-146.
58. Nakashima N, Haji M, Sakai Y, Ono Y, Umeda F, Nawata H: Effect of dehydroepiandrosterone on glucose uptake in cultured human fibroblasts. Metabolism 1995, 44:543-548.
59. A receptor. Neuroscience 1991, 45:127-135.
60. Wright BE, Svec F, Porter JR: Central effects of dehydroepiandrosterone in Zucker rats. Int J Obes 1995, 19:887-892.
61. Azuma T, Matsubara T, Shima Y, Haeno S, Fujimoto T, Tone K, Shibata N, Sakoda S: Neurosteroids in cerebrospinal fluid in neurologic disorders. J Neurol Sci 1993, 120:87-92.
62. Schwartz AG, Lewbart ML, Pashko LL: Novel dehydroepiandrosterone analogues with enhanced biological activity and reduced side effects in mice and rats. Cancer Res 1988, 48:4817-4822.
63. MacEwen EG, Kurzman ID: Obesity in the dog: role of the adrenal steroid dehydroepiandrosterone (DHEA). J Nutr 1991, 121:S51-S55.